Loading the records…
Loading the records…
Merck & Co., Inc. ($MRK) received a $156M definitive contract from HHS/ASPR for ERVEBO (Ebola vaccine) procurement over 10 years. This is a modest but stable revenue addition for Merck, reinforcing its role in biodefense.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
For $MRK, this contract adds a predictable ~$15.6M annual revenue, which is negligible compared to the company's $60.1B top line. However, it reinforces Merck's position in the vaccine and biodefense market, which could support long-term government relationships. No significant stock price movement is expected from this award alone.
This signal is one of the converging government actions below.
Over the last 90 days, 55 separate government actions have converged on Biodefense / Pandemic Preparedness. What that means: federal dollars are already moving — agencies are soliciting bids and awarding contracts, not just talking, and legislation and executive action are building the policy and funding tailwind behind it. When independent channels move together like this — 44 federal contracts, 7 procurement notices, 3 bills and 1 news — it's the clearest early tell that Washington is committing to biodefense / pandemic preparedness, the kind of build-up that reshapes the sector well before it's obvious in the headlines.
Converging government actions
The contract award to Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. ($MRK), is for $156M to procure ERVEBO, the Ebola vaccine. The awarding agency is the Department of Health and Human Services' Office of Assistant Secretary for Preparedness and Response, indicating a biodefense and pandemic preparedness focus. The contract runs from 2024 to 2034, providing a decade-long revenue stream. Merck's FY2025 revenue was $60.1B, so the annualized value of ~$15.6M is less than 0.03% of revenue, making it a small but positive contributor. No related legislation directly ties to this contract; the listed bills are unrelated to Ebola or vaccine procurement. Supply chain beneficiaries are not specified, but potential subcontractors could include contract manufacturing organizations (CMOs) or raw material suppliers, though no specific publicly traded tickers are identified. Historically, biodefense contracts provide stable, recurring revenue for pharmaceutical companies with approved medical countermeasures, often leading to sustained government partnerships.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Direct award for ERVEBO (Ebola vaccine) procurement from HHS/ASPR.
Who must act
Department of Health and Human Services, Office of Assistant Secretary for Preparedness and Response to Merck Sharp & Dohme LLC (Merck & Co., Inc.)
What happens
$156M total contract value over 10 years, representing approximately $15.6M annualized revenue, or ~0.03% of Merck's FY2025 revenue of $60.1B.
Stock impact
Adds a predictable, long-term revenue stream for Merck's vaccine portfolio. While small relative to total revenue, it strengthens Merck's position in biodefense and pandemic preparedness, a strategic growth area.
Matched on shared policy language across AI analyses, with ticker & timing weight
MERCK SHARP & DOHME LLC: $156M Department of Health and Human Services Contract
MERCK SHARP & DOHME LLC: $2.0B Department of Health and Human Services Contract Vehicle
MERCK SHARP & DOHME LLC: $1.8B Department of Health and Human Services Contract Vehicle
MERCK SHARP & DOHME LLC: $2.4B Department of Health and Human Services Contract Vehicle
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Recipient
MERCK SHARP & DOHME LLC
Award Amount
$156,033,983
Awarding Agency
Department of Health and Human Services
Sub-Agency
Office of Assistant Secretary for Preparedness and Response
Contract Type
DEFINITIVE CONTRACT
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →